36
Views
12
CrossRef citations to date
0
Altmetric
Brief report

Efficacy and Safety of Switching from Enfuvirtide to Raltegravir in Patients with Virological Suppression

, , , , , , , , & show all
Pages 432-438 | Published online: 06 Jan 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Massimiliano Fabbiani, Annalisa Mondi, Manuela Colafigli, Gabriella D’Ettorre, Francesca Paoletti, Alessandro D’Avino, Nicoletta Ciccarelli, Letizia Sidella, Rita Murri, Serena Fortuna, Vincenzo Vullo, Roberto Cauda, Andrea De Luca & Simona Di Giambenedetto. (2014) Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scandinavian Journal of Infectious Diseases 46:1, pages 34-45.
Read now

Articles from other publishers (11)

Tianshu Xiao, Gary Frey, Qingshan Fu, Christy L. Lavine, David A. Scott, Michael S. Seaman, James J. Chou & Bing Chen. (2020) HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes. Nature Chemical Biology 16:5, pages 529-537.
Crossref
. (2013) Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2013). Enfermedades Infecciosas y Microbiología Clínica 31:9, pages 602.e1-602.e98.
Crossref
Peter Messiaen, Annemarie M. J. Wensing, Axel Fun, Monique Nijhuis, Nele Brusselaers & Linos Vandekerckhove. (2013) Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis. PLoS ONE 8:1, pages e52562.
Crossref
Caroline Pereira Bittencourt Passaes, Monick Lindenmeyer Guimarães, Sandra Wagner Cardoso, José Henrique Pilotto, Valdilea Veloso, Beatriz Grinsztejn & Mariza Gonçalves Morgado. (2012) Monitoring the emergence of resistance mutations in patients infected with HIV‐1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: A follow‐up study. Journal of Medical Virology 84:12, pages 1869-1875.
Crossref
Caitlin Lee Shamroe, Paul Brandon Bookstaver, Kristina E.E. Rokas & Sharon B. Weissman. (2012) Update on Raltegravir and the Development of New Integrase Strand Transfer Inhibitors. Southern Medical Journal 105:7, pages 370-378.
Crossref
. (2012) Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012). Enfermedades Infecciosas y Microbiología Clínica 30:6, pages e1-e89.
Crossref
Marianne Harris, Bohdan Nosyk, Richard Harrigan, Viviane Dias Lima, Calvin Cohen & Julio Montaner. (2012) Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future. AIDS Research and Treatment 2012, pages 1-8.
Crossref
Matthew Grant, Rafik Samuel, Robert L. Bettiker & Byungse Suh. (2011) Antiretroviral therapy 2010 update: Current practices and controversies. Archives of Pharmacal Research 34:7.
Crossref
Estevao Portela Nunes, Marília Santini de Oliveira & Beatriz Grinsztejn. (2010) Clinical use of raltegravir: a review. HIV Therapy 4:5, pages 531-542.
Crossref
Babafemi Taiwo, Robert L. Murphy & Christine Katlama. (2010) Novel Antiretroviral Combinations in Treatment-Experienced Patients with HIV Infection. Drugs 70:13, pages 1629-1642.
Crossref
. (2010) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 19:7.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.